Evidence map›Paper›PMID 31673058›Full record

ArticleScientific reports2019

Heparin and heparan sulfate proteoglycans promote HIV-1 p17 matrix protein oligomerization: computational, biochemical and biological implications.

Antonella Bugatti, Giulia Paiardi, Chiara Urbinati, Paola Chiodelli, Alessandro Orro, Matteo Uggeri, Luciano Milanesi, Arnaldo Caruso, Francesca Caccuri, Pasqualina D'Ursi and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. The accomplices: Heparan sulfates and N-glycans foster SARS-CoV-2 spike:ACE2 receptor binding and virus priming.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  4. Review
  5. Review
  6. Coreceptor functions of cell surface heparan sulfate proteoglycans.American journal of physiology. Cell physiology · 2022
    Review
  7. Prevention ofPharmaceutics · 2022
    Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Antonella BugattiSection of Microbiology, Department of Molecular and Translational Medicine, School of Medicine, University of Brescia, Brescia, Italy.
Giulia PaiardiSection of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, School of Medicine, University of Brescia, Brescia, Italy.
Chiara UrbinatiSection of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, School of Medicine, University of Brescia, Brescia, Italy.
Paola ChiodelliSection of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, School of Medicine, University of Brescia, Brescia, Italy.
Alessandro OrroInstitute for Biomedical Technologies-National Research Council (ITB-CNR), Segrate, Milan, Italy.ORCID http://orcid.org/0000-0002-2581-9579
Matteo UggeriInstitute for Biomedical Technologies-National Research Council (ITB-CNR), Segrate, Milan, Italy.
Luciano MilanesiInstitute for Biomedical Technologies-National Research Council (ITB-CNR), Segrate, Milan, Italy.ORCID http://orcid.org/0000-0002-1201-3939
Arnaldo CarusoSection of Microbiology, Department of Molecular and Translational Medicine, School of Medicine, University of Brescia, Brescia, Italy.
Francesca CaccuriSection of Microbiology, Department of Molecular and Translational Medicine, School of Medicine, University of Brescia, Brescia, Italy.
Pasqualina D'UrsiInstitute for Biomedical Technologies-National Research Council (ITB-CNR), Segrate, Milan, Italy. pasqualina.dursi@itb.cnr.it.ORCID http://orcid.org/0000-0003-1554-429X
Marco RusnatiSection of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, School of Medicine, University of Brescia, Brescia, Italy. marco.rusnati@unibs.it.ORCID http://orcid.org/0000-0001-9968-5908
University of Brescia · ITInstitute of Biomedical Technologies · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

p17 matrix protein released by HIV+ cells interacts with leukocytes heparan sulfate proteoglycans (HSPGs), CXCR1 and CXCR2 exerting different cytokine-like activities that contribute to AIDS pathogenesis. Since the bioactive form of several cytokines is represented by dimers/oligomers and oligomerization is promoted by binding to heparin or HSPGs, here we evaluated if heparin/HSPGs also promote p17 oligomerization. Heparin favours p17 dimer, trimer and tetramer assembly, in a time- and biphasic dose-dependent way. Heparin-induced p17 oligomerization is of electrostatic nature, being it prevented by NaCl, by removing negative sulfated groups of heparin and by neutralizing positive lysine residues in the p17 N-terminus. A new computational protocol has been implemented to study heparin chains up to 24-mer accommodating a p17 dimer. Molecular dynamics show that, in the presence of heparin, two p17 molecules undergo conformational modifications creating a continuous "electropositive channel" in which heparin sulfated groups interact with p17 basic amino acids, promoting its dimerization. At the cell surface, HSPGs induce p17 oligomerization, as demonstrated by using B-lymphoblastoid Namalwa cells overexpressing the HSPG Syndecan-1. Also, HSPGs on the surface of BJAB and Raji human B-lymphoblastoid cells are required to p17 to induce ERK

Indexed as

gag Gene Products, Human Immunodeficiency VirusHIV-1HIV AntigensMAP Kinase Signaling SystemProtein MultimerizationSyndecan-1Acquired Immunodeficiency SyndromeCell Line, TumorHeparinHumansgag Gene Products, Human Immunodeficiency VirusHeparinHIV Antigensp17 protein, Human Immunodeficiency Virus Type 1SDC1 protein, humanSyndecan-1

Identifiers

PMID31673058
PMCPMC6823450
OpenAlexW2982456072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.